Want to see GYRE full AI Analyst Report?
Top Page
Gyre Therapeutics
(NASDAQ:GYRE)
Select Model
Select Model
Rating:61Neutral
Price Target:
$7.00
▲(5.26% Upside)
Action:Reiterated
Date:09/06/26
The score is primarily supported by a strong, low-debt balance sheet and high gross profitability, but is held back by the TTM shift to net losses and inconsistent operating cash flow. Technicals are moderately constructive (price above key moving averages with positive MACD), while valuation is pressured due to the negative P/E. Positive corporate updates around capital efficiency and pipeline catalysts provide an added, but secondary, tailwind.
Positive Factors
Conservative balance sheet
Very low leverage and a sizable equity base provide financial resilience as Gyre funds clinical development. This reduces near-term balance-sheet risk and preserves flexibility to allocate capital across commercial operations and pipeline programs.
Negative Factors
Return to net losses
The return from positive net income in 2024-2025 to a TTM loss shows that revenue growth is not currently translating consistently into bottom-line earnings. Rising operating costs could continue to absorb gross profit and weaken earnings durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a sizable equity base provide financial resilience as Gyre funds clinical development. This reduces near-term balance-sheet risk and preserves flexibility to allocate capital across commercial operations and pipeline programs.
Read all positive factors
Gyre Therapeutics (GYRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$713.61M
Dividend Yield642.31%
Average Volume (3M)61.01K
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue Growth16.83%
EPS Growth-494.61%
CountryUS
Employees625
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding106,033,760
10 Day Avg. Volume75,006
30 Day Avg. Volume61,011
Financial Highlights & Ratios
PEG Ratio-2.10
Price to Book (P/B)5.95
Price to Sales (P/S)5.41
P/FCF Ratio-3.50K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.00Price Target Upside185.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$102.30M
Gyre Therapeutics Business Overview & Revenue Model
Company Description
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfe...
Gyre Therapeutics Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 119.38M | 116.59M | 105.76M | 113.45M | 102.29M | 7.34M |
| Gross Profit | 112.58M | 111.17M | 101.87M | 108.81M | 97.50M | -332.00K |
| EBITDA | -14.03M | 16.96M | 17.82M | 20.33M | 10.54M | -87.64M |
| Net Income | -17.33M | 5.03M | 12.09M | -92.93M | 2.30M | -87.93M |
Balance Sheet | ||||||
| Total Assets | 199.25M | 166.13M | 125.41M | 116.54M | 84.75M | 55.66M |
| Cash, Cash Equivalents and Short-Term Investments | 74.80M | 52.42M | 26.67M | 33.51M | 25.18M | 46.85M |
| Total Debt | 3.42M | 939.00K | 1.60M | 409.00K | 613.00K | 2.38M |
| Total Liabilities | 34.34M | 23.85M | 27.00M | 102.59M | 12.54M | 14.57M |
| Stockholders Equity | 130.36M | 106.03M | 63.32M | -15.83M | 42.52M | 41.09M |
Cash Flow | ||||||
| Free Cash Flow | -16.79M | -180.00K | -6.77M | 17.31M | 5.68M | -84.59M |
| Operating Cash Flow | -14.50M | 1.01M | -3.64M | 25.89M | 10.68M | -83.75M |
| Investing Cash Flow | 7.30M | -474.00K | -19.88M | -19.76M | -13.81M | 48.19M |
| Financing Cash Flow | 696.00K | 24.38M | 2.10M | 2.50M | 0.00 | 49.55M |
Gyre Therapeutics Technical Analysis
Neutral
6.65
Price Trends
6.51
Positive
6.57
Positive
7.13
Negative
Market Momentum
0.09
Negative
52.08
Neutral
51.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Neutral. The current price of 6.65 is below the 20-day moving average (MA) of 6.74, above the 50-day MA of 6.51, and below the 200-day MA of 7.13, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 52.08 is Neutral, neither overbought nor oversold. The STOCH value of 51.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GYRE.
Gyre Therapeutics Risk Analysis
Gyre Therapeutics disclosed 98 risk factors in its most recent earnings report. Gyre Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gyre Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
GYRE
Gyre Therapeutics
6.73
-1.17
-14.81%
TYRA
Tyra Bioscience
22.03
9.72
78.96%
MBX
MBX Biosciences, Inc.
59.02
48.15
442.96%
Gyre Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy
Positive
Sep 1, 2026
On September 1, 2026, Gyre Therapeutics made an updated corporate presentation available, highlighting a global, capital‑efficient development model that uses revenue from its established China commercial operations to help fund early-stage ...
Business Operations and Strategy
Gyre Therapeutics unveils capital-efficient global development strategy
Positive
Aug 26, 2026
On August 26, 2026, Gyre Therapeutics released an updated corporate presentation detailing a capital-efficient global development strategy that uses revenue from its established China operations, including the market-leading IPF drug ETUARY, to he...
Business Operations and StrategyExecutive/Board Changes
Gyre Therapeutics Strengthens Board with New Director Appointments
Positive
Jul 17, 2026
On July 10, 2026, Gyre Therapeutics’ board appointed Chief Scientific Officer Yue Xiong, Ph.D., consultant Maxwell Kirkby and AI healthcare executive Claire Weston, Ph.D., to Class I, II and III director seats effective August 1, 2026. Kirkb...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Gyre Therapeutics Shareholders Approve Directors and Governance Measures
Positive
Jun 16, 2026
On June 10, 2026, Gyre Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, at which shareholders elected Class II directors David M. Epstein, Ph.D., and Dan Weng, M.D., to serve until the 2029 annual meeting and approved, on a non-bin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.